Endonovo Therapeutics, Inc. (ENDV) stock
ENDVOTCElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q3 FY2023, quarter ended Sep 30, 2023Last filing: 10-Q/A on Dec 29, 2023
$0.00+0.00 (0.00%)
Close on Oct 19, 2026Market cap $135.08KP/E –Yield –
Endonovo Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Endonovo Therapeutics's R&D Expenses for the twelve months ending Dec 31, 2021 was $0, down 100.0% year over year. For fiscal 2021 it was $0, down 100.0% from the year before. The highest annual figure on record is $274.27K in fiscal 2018.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $0 | -100.0% |
| FY2020 | Dec 31, 2020 | $3.28K | -97.9% |
| FY2019 | Dec 31, 2019 | $153.13K | -44.2% |
| FY2018 | Dec 31, 2018 | $274.27K | +138.2% |
| FY2017 | Dec 31, 2017 | $115.16K | – |
| FY2016 | Dec 31, 2016 | $0 | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2021 | Dec 31, 2021 | $0 | – |
| Q3 FY2021 | Sep 30, 2021 | $0 | – |
| Q2 FY2021 | Jun 30, 2021 | $0 | -100.0% |
| Q1 FY2021 | Mar 31, 2021 | $0 | -100.0% |
| Q4 FY2020 | Dec 31, 2020 | $0 | -100.0% |
| Q3 FY2020 | Sep 30, 2020 | $0 | -100.0% |
| Q2 FY2020 | Jun 30, 2020 | $2.28K | -96.4% |
| Q1 FY2020 | Mar 31, 2020 | $1.00K | -99.1% |
| Q4 FY2019 | Dec 31, 2019 | $65.10K | +1142.9% |
| Q3 FY2019 | Sep 30, 2019 | $34.71K | -20.6% |
| Q1 FY2019 | Mar 31, 2019 | $63.30K | -44.5% |
| Q4 FY2018 | Dec 31, 2018 | $111.19K | – |
| Q3 FY2018 | Sep 30, 2018 | $5.24K | -93.0% |
| Q2 FY2018 | Jun 30, 2018 | $43.73K | – |
| Q1 FY2018 | Mar 31, 2018 | $114.11K | – |
| Q4 FY2017 | Dec 31, 2017 | $0 | – |
| Q3 FY2017 | Sep 30, 2017 | $75.35K | – |
| Q2 FY2017 | Jun 30, 2017 | $0 | – |
| Q1 FY2017 | Mar 31, 2017 | $0 | – |
See a number that looks wrong?